Tacrolimus exposure during the three-month period following allogeneic stem cell transplantation predicts overall survival
Except for the disease risk category, age, and non-myeloablative conditioning, exposure to tacrolimus is an independent predictor of overall survival and should not exceed trough levels of 10.7 ng/mL during the second month and 6.8 ng/mL during third month after transplantation. In order to reach this target, nomogram for estimation of the maximal initial tacrolimus daily dose was developed based on the population pharmacokinetic model.
Authors
- Ondřej Slanař (ORCID: https://orcid.org/0000-0002-5357-7562)
- Eva Čermáková (ORCID: https://orcid.org/0000-0003-3413-4149)
- Benjamín Víšek (ORCID: https://orcid.org/0000-0001-8268-452X)
- Petra Rozsívalová (ORCID: https://orcid.org/0000-0001-6114-3871)
- Jakub Radocha (ORCID: https://orcid.org/0000-0002-5384-8238)
- Alžběta Zavřelová
- Sara Merdita (ORCID: https://orcid.org/0000-0001-7516-9423)
- Miriam Lánská (ORCID: https://orcid.org/0000-0002-8453-1153)
- Martin Šíma (ORCID: https://orcid.org/0000-0002-6541-738X)
- Павел Зак (ORCID: https://orcid.org/0000-0003-4465-5343)
- Jana Števková
- Katerina Zibridova
Institutions
- Charles University (CZ)
- University Hospital Hradec Králové (CZ)
- General University Hospital in Prague (CZ)
- University of Hradec Králové (CZ)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.3389/fphar.2025.1517083
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Univerzita Karlova v Praze
- Agentura Pro Zdravotnický Výzkum České Republiky